Corbus Triggers Bearish KDJ Death Cross and Bearish Marubozu on 15-Minute Chart

Wednesday, Oct 8, 2025 2:32 pm ET1min read

Corbus's 15-minute chart has recently triggered a KDJ Death Cross and a Bearish Marubozu pattern on October 8th at 14:30. This indicates a shift in the momentum of the stock price towards a downward trend, suggesting a potential decrease in the stock's value in the near future. The market is currently under the control of sellers, and it is likely that this bearish momentum will continue.

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a biotechnology company focused on precision oncology, has recently experienced a significant shift in its stock price momentum. On October 8th at 14:30, the 15-minute chart of Corbus Pharmaceuticals triggered a KDJ Death Cross and a Bearish Marubozu pattern. These technical indicators suggest a potential downward trend in the stock's value, indicating that the market is currently under the control of sellers.

The KDJ Death Cross, which is a combination of the K-line and D-line crossing below the J-line, signals a change in the stock's momentum from bullish to bearish. The Bearish Marubozu pattern, characterized by a long white candle with no shadows, indicates a strong selling pressure. These patterns suggest that the stock may continue to decline in the near future.

The stock has been performing well recently, with a 13.99% increase in the past five days and a 22.46% increase since January 1st. However, the recent technical indicators suggest a potential reversal in the stock's upward trend. Investors should closely monitor the stock's performance and be prepared for potential volatility.

Corbus Pharmaceuticals has been in the news recently for its clinical trials and FDA designations. The company has received FDA Fast-Track Designation for its Nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma treatment Top Premarket Decliners[1]. Additionally, the company has announced upcoming presentations of its clinical data at the 2025 ESMO Annual Congress .

Comments



Add a public comment...
No comments

No comments yet